498 related articles for article (PubMed ID: 31211526)
1. Assessing the burden of illness of chronic hepatitis C and impact of direct-acting antiviral use on healthcare costs in Medicaid.
Roebuck MC; Liberman JN
Am J Manag Care; 2019 Jun; 25(8 Suppl):S131-S139. PubMed ID: 31211526
[TBL] [Abstract][Full Text] [Related]
2. Healthcare Costs for Chronic Hepatitis C in South Korea from 2009 to 2013: An Analysis of the National Health Insurance Claims' Data.
Ki M; Choi HY; Kim KA; Jang ES; Jeong SH
Gut Liver; 2017 Nov; 11(6):835-842. PubMed ID: 28798283
[TBL] [Abstract][Full Text] [Related]
3. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective.
McAdam-Marx C; McGarry LJ; Hane CA; Biskupiak J; Deniz B; Brixner DI
J Manag Care Pharm; 2011 Sep; 17(7):531-46. PubMed ID: 21870894
[TBL] [Abstract][Full Text] [Related]
4. The Economic Burden of End-Organ Damage Among Medicaid Patients with Sickle Cell Disease in the United States: A Population-Based Longitudinal Claims Study.
Campbell A; Cong Z; Agodoa I; Song X; Martinez DJ; Black D; Lew CR; Varker H; Chan C; Lanzkron S
J Manag Care Spec Pharm; 2020 Sep; 26(9):1121-1129. PubMed ID: 32597290
[TBL] [Abstract][Full Text] [Related]
5. Burden of illness in patients with possible Lennox-Gastaut syndrome: A retrospective claims-based study.
Reaven NL; Funk SE; Montouris GD; Saurer TB; Story TJ
Epilepsy Behav; 2018 Nov; 88():66-73. PubMed ID: 30241056
[TBL] [Abstract][Full Text] [Related]
6. Healthcare resource utilization and costs by disease severity in an insured national sample of US patients with chronic hepatitis B.
Nguyen MH; Burak Ozbay A; Liou I; Meyer N; Gordon SC; Dusheiko G; Lim JK
J Hepatol; 2019 Jan; 70(1):24-32. PubMed ID: 30287341
[TBL] [Abstract][Full Text] [Related]
7. The burden of hepatitis C to the United States Medicare system in 2009: Descriptive and economic characteristics.
Rein DB; Borton J; Liffmann DK; Wittenborn JS
Hepatology; 2016 Apr; 63(4):1135-44. PubMed ID: 26707033
[TBL] [Abstract][Full Text] [Related]
8. Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection.
Gordon SC; Pockros PJ; Terrault NA; Hoop RS; Buikema A; Nerenz D; Hamzeh FM
Hepatology; 2012 Nov; 56(5):1651-60. PubMed ID: 22610658
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis C Cure Is Associated with Decreased Healthcare Costs in Cirrhotics in Retrospective Veterans Affairs Cohort.
Maier MM; Zhou XH; Chapko M; Leipertz SL; Wang X; Beste LA
Dig Dis Sci; 2018 Jun; 63(6):1454-1462. PubMed ID: 29453610
[TBL] [Abstract][Full Text] [Related]
10. Impact of completing chronic hepatitis C (CHC) treatment on post-therapy healthcare cost.
Tandon N; Balart LA; Laliberté F; Pilon D; Lefebvre P; Germain G; Prabhakar A
J Med Econ; 2014 Dec; 17(12):862-71. PubMed ID: 25215925
[TBL] [Abstract][Full Text] [Related]
11. The cost of Medicaid-covered services provided to disabled adults with neurologic disorders: implications for managed care.
Gardner EN; Murtaugh CM; Ray NF; Thamer M
Am J Manag Care; 1999 Nov; 5(11):1417-25. PubMed ID: 10662415
[TBL] [Abstract][Full Text] [Related]
12. Direct-Acting Antiviral Treatment Use Remains Low Among Florida Medicaid Beneficiaries With Chronic Hepatitis C.
Park H; Song HJ; Jiang X; Henry L; Cook RL; Nelson DR
Hepatol Commun; 2021 Feb; 5(2):203-216. PubMed ID: 33553969
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland.
Blach S; Schaetti C; Bruggmann P; Negro F; Razavi H
Swiss Med Wkly; 2019 Mar; 149():w20026. PubMed ID: 30905063
[TBL] [Abstract][Full Text] [Related]
14. Health care utilization and costs associated with direct-acting antivirals for patients with substance use disorders and chronic hepatitis C.
Jiang X; Vouri SM; Diaby V; Lo-Ciganic W; Parker R; Park H
J Manag Care Spec Pharm; 2021 Oct; 27(10):1388-1402. PubMed ID: 34595949
[No Abstract] [Full Text] [Related]
15. Scenarios to manage the hepatitis C disease burden and associated economic impact of treatment in Turkey.
Örmeci N; Malhan S; Balık İ; Ergör G; Razavi H; Robbins S
Hepatol Int; 2017 Nov; 11(6):509-516. PubMed ID: 29027109
[TBL] [Abstract][Full Text] [Related]
16. State Medicaid Reimbursement for Medications for Chronic Hepatitis C Infection from 2012 through 2015.
Lu CY; Zhang F; Golonski N; Lupton C; Jeffrey P; Wagner AK
Value Health; 2018 Jun; 21(6):692-697. PubMed ID: 29909874
[TBL] [Abstract][Full Text] [Related]
17. Cost of treating hepatitis C in Germany: a retrospective multicenter analysis.
Stahmeyer JT; Rossol S; Bert F; Antoni C; Demir M; Hinrichsen H; Hüppe D; Teuber G; Wiebner B; Wedemeyer H; Krauth C
Eur J Gastroenterol Hepatol; 2014 Nov; 26(11):1278-85. PubMed ID: 25144493
[TBL] [Abstract][Full Text] [Related]
18. The economic burden of advanced liver disease among patients with hepatitis C virus: a large state Medicaid perspective.
Menzin J; White LA; Nichols C; Deniz B
BMC Health Serv Res; 2012 Dec; 12():459. PubMed ID: 23241078
[TBL] [Abstract][Full Text] [Related]
19. Association of Medicaid Managed Care Drug Carve Outs With Hepatitis C Virus Prescription Use.
Auty SG; Shafer PR; Dusetzina SB; Griffith KN
JAMA Health Forum; 2021 Aug; 2(8):e212285. PubMed ID: 35977199
[TBL] [Abstract][Full Text] [Related]
20. Health Care Utilization and Costs Associated with Endometriosis Among Women with Medicaid Insurance.
Soliman AM; Surrey ES; Bonafede M; Nelson JK; Vora JB; Agarwal SK
J Manag Care Spec Pharm; 2019 May; 25(5):566-572. PubMed ID: 31039061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]